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642Aneurysmal disease is associated with lower carotid
intima-media thickness than occlusive arterial
disease
Koen M. van de Luijtgaarden, MD,a,b Erik J. Bakker, MD,b Ellen V. Rouwet, MD, PhD,a
Sanne E. Hoeks, PhD,b Tabita M. Valentijn, MD,b Robert J. Stolker, MD, PhD,b
Danielle Majoor-Krakauer, MD, PhD,c and Hence J. M. Verhagen, MD, PhD,a Rotterdam, The Netherlands
Objective: Patients with aneurysmal and occlusive arterial disease have overlapping cardiovascular risk proﬁles. The
question remains how atherosclerosis is related to the formation of aortic aneurysms. Common carotid artery intima-
media thickness (CIMT) is an easily accessible and objective marker of early atherosclerosis. The aim of the current
study was to investigate whether there is a difference in atherosclerotic burden as measured by CIMT between patients
with aneurysmal and those with occlusive arterial disease.
Methods: From 2004 to 2011, the CIMT was measured using B-mode ultrasound scanning in patients undergoing
vascular surgery for aortic aneurysmal or occlusive arterial disease at the Erasmus University Medical Center. Cardio-
vascular risk factors, comorbidities, and medication were recorded. Patients treated for combined aneurysmal and
occlusive arterial disease and patients diagnosed with a genetic aneurysm syndrome were excluded. Univariable and
multivariable analyses were used to calculate differences in CIMT between aneurysmal and occlusive arterial disease.
Results: In total, 904 patients were included in the study: 502 patients with aneurysmal disease (85% male; mean age, 72
years) and 402 patients with occlusive arterial disease (65% male; mean age, 64 years). The mean (standard deviation)
CIMT in patients with aneurysmal disease was 0.97 (0.29) mm and was 1.07 (0.38) mm in patients with occlusive arterial
disease (P < .001). Adjustment for cardiovascular risk factors, comorbidities, and medication showed a mean difference in
CIMT of 0.15 mm (95% conﬁdence interval, 0.10-0.20; P < .001).
Conclusions: The current study shows a lower CIMT in patients with aneurysmal disease than in those with occlusive
arterial disease, indicating a lower atherosclerotic burden in patients with aneurysmal disease. These ﬁndings endorse the
idea that additional pathogenic mechanisms are involved in aortic aneurysm formation. Further studies are needed to
clarify the role of atherosclerosis in aortic aneurysm formation. (J Vasc Surg 2013;57:642-7.)It is well known that aortic aneurysm disease is corre-
lated with systemic atherosclerotic disease. Patients with
aneurysmal disease and those with occlusive arterial
diseases, including ischemic heart disease, carotid artery
stenosis, and peripheral arterial disease (PAD), have over-
lapping cardiovascular risk proﬁles. Furthermore, patients
with an abdominal aortic aneurysm (AAA) have a high
degree of coronary artery disease as well as atherosclerotic
changes in the aortic wall.1,2
However, a causal relation between atherosclerosis and
aneurysmal disease has not been established. Most patients
with atherosclerotic disease do not develop an aneurysm,the Department of Vascular Surgery,a the Department of Anesthe-
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://dx.doi.org/10.1016/j.jvs.2012.09.015and aneurysmal disease is not always associated with periph-
eral arterial, carotid, or coronary disease.1 Second, although
conventional cardiovascular risk factors, such as age, male
gender, diabetes mellitus, hypertension, smoking, and dysli-
pidemia, are often observed in patients with aneurysmal
disease, a number of studies report conﬂicting results on
the relationship between these risk factors and AAAs.3-5
Next, atherosclerosis affects predominantly the intimal and
medial layers of the vascular wall, whereas in aneurysmal
disease, pathologic changes also involve the adventitial layer.
High proteolytic activity, destruction of collagen and elastin,
andmassive inﬁltration of inﬂammatory cells are characteris-
tics of an aneurysmal arterial wall.6 Given the epidemiologic,
biochemical, and structural differences between aneurysmal
and occlusive arterial disease, the conventional view of aneu-
rysm formation as a consequence of atherosclerosis is
currently challenged.7
The aim of the current study was to investigate whether
there is a difference in atherosclerotic burden between
patients with aneurysmal disease and those with occlusive
arterial disease. The atherosclerotic burden was determined
by measuring the common carotid artery intima-media
thickness (CIMT) using B-mode ultrasound scanning.
Thickening of the intimal and medial layers of the common
carotid artery is an early expression of generalized athero-
sclerosis.8,9 In addition, CIMT serves as a risk predictor
for cardiovascular and cerebrovascular events.10,11
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Study population. The study population consisted of
patients undergoing elective open or endovascular surgery
for aortic aneurysmal disease or for occlusive arterial
disease, between 2004 and 2011 in the Erasmus University
Medical Center in Rotterdam, The Netherlands. The aortic
aneurysmal disease population was deﬁned as patients
having an aortic and/or thoracic aortic aneurysm with
a diameter >55 mm or >60 mm, respectively. The occlu-
sive arterial disease population was deﬁned as patients with
symptomatic PAD, which included patients with intermit-
tent claudication or critical limb ischemia in combination
with a resting and/or postexercise ankle-brachial
index <0.9 and/or imaging ﬁndings compatible with the
clinical symptoms. Patients treated for combined aneu-
rysmal and occlusive arterial disease and patients diagnosed
with a genetic aneurysm (eg, Marfan, Loeys-Dietz, or
vascular Ehlers-Danlos syndrome) were excluded. The
study complied with the Declaration of Helsinki and was
approved by the Institutional Review Board.
Patient characteristics. Patients were prospectively
enrolled, and the following characteristics were recorded
for all patients as part of routine clinical practice before
surgery, including the cardiovascular risk factors: age,
gender, body mass index, hypertension (blood pressure
$140/90 mm Hg in nondiabetics, $130/80 mm Hg in
diabetics, or use of antihypertensive medication), hypercho-
lesterolemia (low-density lipoprotein cholesterol $3.5
mmol/L, or use of lipid-lowering medication), diabetes
mellitus (fasting plasma glucose $7.0 mmol/L, nonfasting
glucose$11.1 mmol/L, or use of antidiabetic medication),
smoking status, and kidney disease (serum creatinine $2.0
mg/dL). Furthermore, cardiovascular comorbidities were
recorded, including congestive heart failure, ischemic heart
disease (history of angina pectoris, myocardial infarction,
coronary revascularization, or pathologic Q waves on the
electrocardiogram), and cerebrovascular disease (history of
ischemic/hemorrhagic stroke or transient ischemic attack).
Furthermore, prescription medications were recorded,
including statins, b-blockers, renin–angiotensin system
inhibitors, diuretics, and antiplatelet drugs.
Atherosclerotic marker. The severity of atheroscle-
rotic disease was assessed by measurements of the CIMT
prior to surgery using B-mode ultrasound scanning accord-
ing to the guidelines from the Mannheim Carotid Intima-
Media Thickness Consensus.12,13 Patients were examined
in the supine position with the head turned 45 away from
the side being scanned and the neck extended slightly. A
longitudinal view of the right and left common carotid
artery was obtained using a portable SonoSite Titan Ultra-
sound System (SonoSite Inc, Bothell, Wash) with an L38-
10-5 MHz linear ultrasound transducer or a portable
Vivid-I Ultrasound System (Vivid-I; GE Healthcare, Sol-
ingen, Germany) with an 8L-RS transducer. Several
measurements were made along a minimum of 10 mm at
the posterior wall of the right and left common carotid
artery. The intima-media thickness was calculated onlineby built-in software of the ultrasound system from the
interface between the lumen and intima to the interface
between media and adventitia. The maximum CIMT value
of both common carotid arteries was used for the analysis.
Atherosclerotic plaques, deﬁned as focal structures of at least
0.5 mm encroaching into the arterial lumen, were excluded
from analysis.13 The sonographers who performed the
measurements were blinded for the clinical characteristics of
the patients and had an interobserver correlation of 96.2%.12
Statistical analysis. Dichotomous data are presented as
number and percentage. Continuous variables are presented
as mean (standard deviation) or median (interquartile range)
when not normally distributed. Categorical data were
analyzed with the c2 test and continuous variables with anal-
ysis of variance or Kruskal-Wallis test, as appropriate. Linear
univariable and multivariable regression analyses were per-
formed to evaluate the difference in CIMT between patients
with aneurysmal and those with occlusive arterial disease.
Multivariable analyses were adjusted for age, gender, body
mass index, congestive heart failure, ischemic heart disease,
cerebrovascular disease, kidney disease, diabetes mellitus,
hypercholesterolemia, hypertension, current smoking, and
use of statins, b-blockers, renin–angiotensin system inhibi-
tors, diuretics, and antiplatelet drugs. Additionally, interac-
tion between signiﬁcant differences in medication use
(statins, b-blockers and antiplatelet drugs) and CIMT was
tested and, because of nonsigniﬁcance, not included in the
ﬁnal model. Covariates were chosen on the basis of biologic
plausibility. Multivariable binary logistic regression analysis
was used to calculate associations between aneurysmal and
occlusive arterial disease. Covariates in the model were the
same cardiovascular risk factors, comorbidities, and medi-
cation as used in the multivariable linear analyses.
For all tests, P < .05 (two-sided) was considered signif-
icant. All analyses were performed using IBM SPSS Statis-
tics (version 20.0; SPSS Inc, Chicago, Ill).
RESULTS
A total of 904 patients were included in the study: 502
patients with aneurysmal disease and 402 patients with
occlusive arterial disease. The characteristics of the patient
populations are listed in Table I.
Atherosclerotic marker. The mean CIMT in the pop-
ulation was 1.02 (0.33) mm (Table I). Patients with
aneurysmal disease had a mean CIMT of 0.97 (0.29) mm
(median, 0.96 mm; interquartile range, 0.8-1.2), whereas
patients with occlusive arterial disease had a mean CIMT of
1.07 (0.38) mm (median, 1.0 mm; interquartile range, 0.8-
1.3). Univariate regression analysis showed a mean differ-
ence in CIMT of 0.09 mm (95% conﬁdence interval [CI],
0.05-0.14; P < .001; Table II). After adjustment for
potentially confounding factors, this difference increased to
0.15 mm (95% CI, 0.10-0.20; P < .001).
The presence of cerebrovascular disease correlated with
the CIMT in multivariable linear regression analysis (b ¼
.03; 95% CI, 0.01-0.13; P ¼ .022). In addition, the cardio-
vascular risk factors age (b ¼ .01; 95% CI, 0.00-0.01;
Table II. Differences in CIMT between aneurysmal and
occlusive arterial disease
Atherosclerotic marker b 95% CI for b P value
CIMT
Unadjusted .09 .05-.14 <.001
Adjusteda .15 .10-.20 <.001
CI, Conﬁdence interval; CIMT, common carotid intima-media thickness.
aAdjusted for age, gender, body mass index, congestive heart failure,
ischemic heart disease, cerebrovascular disease, kidney disease, diabetes
mellitus, hypertension, current smoking, and use of statins, b-blockers,
renin–angiotensin system inhibitors, diuretics, and antiplatelet drugs.
Table I. Baseline characteristics of patients with aneurysmal and occlusive arterial disease
Total population
(n ¼ 904)
Aneurysmal disease
(n ¼ 502)
Occlusive disease
(n ¼ 402) P value
Baseline characteristic
Male gender, % 685 (75.8) 425 (84.7) 260 (64.7) <.001
Age, mean (SD), years 68.4 (10.1) 71.6 (7.8) 64.4 (11.2) <.001
Body mass index, mean (SD), kg/m2 26.0 (4.2) 26.0 (3.8) 26.0 (4.5) .920
Cardiovascular comorbidity, %
Congestive heart failure 106 (11.7) 51 (10.1) 55 (13.6) .428
Ischemic heart disease 380 (42.0) 217 (43.2) 163 (40.5) .417
Cerebrovascular disease 142 (15.7) 70 (13.9) 72 (17.9) .103
Cardiovascular risk factor, %
Kidney disease 141 (15.5) 75 (14.9) 66 (16.4) .543
Diabetes mellitus 213 (23.5) 77 (15.3) 136 (33.8) <.001
Hypertension 610 (67.4) 342 (68.1) 268 (66.6) .655
Hypercholesterolemia 800 (88.4) 436 (86.8) 364 (98.0) .084
Smoking, current 393 (43.4) 197 (39.2) 196 (48.7) .004
Smoking, ever 683 (75.5) 392 (78.0) 329 (81.8) .163
Medication, %
Statin 688 (76.1) 363 (72.3) 325 (80.8) .004
b-blocker 748 (82.7) 428 (85.2) 320 (79.6) .022
Renineangiotensin system inhibitor 415 (45.9) 226 (45.0) 189 (47.0) .577
Diuretic 214 (23.6) 108 (21.5) 106 (26.3) .092
Antiplatelet drug 591 (65.3) 297 (59.1) 294 (73.1) <.001
Atherosclerotic marker
CIMT, mean (SD), mm 1.02 (0.33) 0.97 (0.29) 1.07 (0.38) <.001
CIMT, Common carotid intima-media thickness; SD, standard deviation.
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.001), and hypercholesterolemia (b ¼ .10; 95% CI, 0.01-
0.19; P ¼ .025) also correlated with CIMT, as did statin
use (b ¼ –.08; 95% CI, –0.14 to –0.01; P ¼ .020).
Associations with aneurysmal and occlusive
disease. Multivariable binary logistic regression analysis
showed that CIMT (per 1 mm) was associated with occlu-
sive arterial disease (odds ratio [OR], 4.5; 95% CI, 2.6-7.7;
P < .001; Fig). Furthermore, diabetes mellitus (OR, 3.0;
95% CI, 2.1-4.5; P < .001) was also associated with
occlusive arterial disease, whereas increased age (OR, 0.91;
95% CI, 0.89-0.92; P < .001) and male gender (OR, 0.25;
95% CI, 0.17-0.37; P < .001) were associated with aneu-
rysmal disease.
DISCUSSION
The results of the current study show that patients with
aneurysmal disease have a lower CIMT than patients withocclusive arterial disease. This indicates that the atheroscle-
rotic burden is less in patients with aneurysmal disease than
in patients with occlusive arterial disease despite their over-
lapping cardiovascular risk proﬁles.
The CIMT measurement was developed for easily
accessible, noninvasive visualization of early stages of
atherosclerosis. Atherosclerotic disease starts with asymp-
tomatic lesions in the arterial wall, including the carotid
arteries.14 Under the inﬂuence of cardiovascular risk
factors, early atherosclerotic changes progress to severe
atherosclerotic changes in the arterial wall. The CIMT
measures the thickness of the intimal and medial layers of
the carotid artery using ultrasound scanning, which has
been shown to correlate well with histologic ﬁndings of
atherosclerosis.15 The CIMT is considered a marker for
generalized atherosclerosis, which, among others, is based
on a study showing the correlation between atherosclerotic
lesions in the coronary arteries and increased IMT in the
common carotid artery.13,16 Increased CIMT is associated
with cardiovascular risk factors, including hypertension,
smoking, diabetes mellitus, and dyslipidemia.17 In addi-
tion, several studies report a correlation between high
CIMT and ischemic events such as coronary events,18 cere-
brovascular events,19 a combination of coronary and cere-
brovascular events,20 and postoperative cardiovascular
events.12 Aminbakhsh et al20 concluded that a rise in
CIMT of 0.03 mm per year was associated with an overall
increased risk of ischemic events. Moreover, Lorenz et al21
reported in a meta-analysis that an absolute CIMT differ-
ence of 0.1 mm, the future risk for myocardial infarction
increases with 10% to 15%, and the risk for stroke increases
Table III. Studies presenting mean difference in CIMT
between patients with aneurysmal disease and peripheral
arterial disease
Year of
publication
No. of
patients
Mean CIMT
difference, mm
Simons et al28 1999 172 0.18b
Spring et al27 2006 67 0.03a
Cheuk et al29 2007 169 0.16b
van de Luijtgaarden
et al
2012 904 0.15c
CIMT, Common carotid intima-media thickness.
aUnivariable difference.
bAge- and gender-adjusted difference.
cMultivariable-adjusted difference.
Fig. Multivariable logistic analysis for aneurysmal vs occlusive
arterial disease. Adjusted for age, gender, body mass index (BMI),
congestive heart failure, ischemic heart disease, cerebrovascular
disease, kidney disease, diabetes mellitus, hypertension, current
smoking, and use of statins, b-blockers, renin–angiotensin system
inhibitors, diuretics, and antiplatelet drugs. CI, Conﬁdence
interval; CIMT, common carotid artery intima-media thickness;
OR, odds ratio.
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lipidemia, may decrease CIMT and reduce the risk of
cardiovascular events.22,23 Although most studies assume
linearity between CIMT and risk for events, Lorenz
et al21 found that the relationship was nonlinear. Neverthe-
less, they concluded that linear models ﬁtted well for
moderate-to-high CIMT values.21 In addition, because
there is a lack of uniformity in its deﬁnition and the meth-
odology used, no CIMT threshold value for high CIMT
has been established.12,24 Taken together, these data
show a strong association between increased CIMT and
the presence and severity of atherosclerotic disease and
indicate that measurement of the CIMT is a valuable clin-
ical tool for assessment of subclinical atherosclerosis and
prediction of the risk for ischemic events.24,25
The mean CIMT in patients with aneurysmal and
occlusive arterial disease was 0.97 and 1.07 mm, respec-
tively, which resembles an absolute difference of about
10%. In the Rotterdam study, which investigated determi-
nants of atherosclerotic disease in the general population,
the mean CIMT in healthy people with a mean age of 71
(9) years was 0.79 mm.11 Another study of a healthy pop-
ulation in the United Kingdom reported an upper limit of
0.81 mm for the CIMT in participants 60 years or older.26
In contrast to the established relationship between CIMTand atherosclerosis, the results of previous studies on
CIMT in patients with aneurysmal disease are conﬂicting.
One study showed a similar increase in CIMT in patients
with symptomatic PAD and in patients with AAAs
compared with healthy controls (Table III).27 Two other
studies reported that patients with AAAs had a 0.16- to
0.18-mm lower mean adjusted CIMT than PAD
patients.28,29 The current study, which is the largest to
date, clearly demonstrates a lower CIMT in patients with
aneurysmal disease than in those with occlusive arterial
disease, even when corrected for all known factors that
might affect the CIMT, including cardiovascular risk
factors, comorbidities, and medication. Hence, the results
of the study indicate that patients with aneurysmal disease
have a lower atherosclerotic burden than patients with
occlusive arterial disease. Nevertheless, CIMT values in
the aneurysm patients were higher when compared with
previously reported CIMT values in age-matched general
populations, an indication that patients with aneurysmal
disease were not free of atherosclerosis.
In addition to differences inCIMT, the current study also
found differences in several cardiovascular risk factors and
comorbidities between aneurysmal and occlusive arterial
disease patients in multivariable analysis. In line with previous
reports, age andmale genderwere associatedwith aneurysmal
disease.30,31 It is known that with advancing age, the inci-
dence of aortic aneurysms increases and thatmen are at higher
risk for AAAs compared with women. Although the true
cause for this matter is still unclear, it seems that genetic
susceptibility and risk factor exposure contribute to this
phenomenon.32 Furthermore, also in line with previous
reports was the lower prevalence of diabetes mellitus
compared with patients having occlusive arterial disease.33
Although diabetes is a risk factor for atherosclerosis, it seems
protective for aortic aneurysm formation.34 Exact mecha-
nisms for this effect are still unclear, but therapeutic agents
for diabetes might stabilize the arterial wall, in order to
prevent dilatation.35 No differences in hypercholesterol-
emia, hypertension, and smoking were observed be-
tween the two patient populations.
Remarkably, the number of patients using statins and
antiplatelet drugs was signiﬁcantly lower among patients
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arterial disease. However, given the high cardiovascular
risk proﬁle in aortic aneurysm patients, the treatment of
these patients should include antiplatelet and statin therapy
as part of their cardiovascular risk management.30
It is still unclear why some people develop aneurysmal
disease, whereas others develop occlusive arterial disease,
despite similarities in their cardiovascular risk proﬁles.
Because not all patients with atherosclerosis develop aortic
aneurysms, there is ongoing discussion as to whether aneu-
rysmal disease is pathogenetically linked to atherosclerosis
or whether the two arterial diseases should be considered
as separate entities.36,37 Even if the classic risk factors for
atherosclerosis may inﬂuence the evolution and develop-
ment of aneurysms, the observed difference in CIMT
suggests that additional factors are involved in the patho-
genesis of aneurysmal disease. About 15% of the AAA
patients have a positive family history, which indicates
that genetic predisposition plays an important role in aneu-
rysmal disease.38 However, no major genetic causes for
AAAs have yet been identiﬁed.39
Our study has some limitations. First, as stated earlier,
an important difﬁculty with the CIMT measurement is the
lack of uniformity in its deﬁnition and the methodology
used, which limits quantitative comparisons of absolute
CIMT values between studies.13 In particular, because
AAA patients are not free of atherosclerosis, it would be
interesting to compare the CIMT values between patients
with aneurysmal disease and those of a propensity score-
matched control group. Second, patients with PAD might
have had higher rates of carotid artery stenosis and, hence,
elevated CIMT. However, high CIMT and carotid artery
stenosis are not similar in terms of localization, natural
history, risk factors, and predictive value for vascular events.
Furthermore, in the current study, the CIMT was
measured in the common carotid artery, whereas carotid
artery stenosis usually is located in the internal carotid
artery. In addition, the rates of symptomatic cerebrovas-
cular disease (stroke, transient ischemic attack) were similar
in patients with aneurysmal disease and those with PAD,
whereas patients who underwent surgery for carotid artery
stenosis were excluded from the study. Third, no system-
atic screening was performed for the genetic defects
causing Marfan, Loeys-Dietz, or vascular Ehlers-Danlos
syndrome, so patients with speciﬁc genetic aneurysm
syndromes might have been included in the study.
However, the contribution of these syndromes to the study
population is probably very small because these syndromes
are rare causes of aortic aneurysms. In addition, the mean
age of patients with aneurysmal disease is much higher
than that of patients with occlusive arterial disease, and
patients with the genetic aneurysm syndromes mentioned
are generally diagnosed at a younger age.40
CONCLUSIONS
The current study shows a lower CIMT in patients with
aneurysmal disease than in patients with occlusive arterial
disease, indicating a lower atherosclerotic burden in patientswith aneurysmal disease. Further research is needed to gain
insight into the complex transcriptional mechanisms under-
lying aneurysm development, in particular, the diverging
processes that lead to dilating or occlusive arterial disease
in the presence of common cardiovascular risk factors.
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